{'fraction_non_alphanumeric': 0.023277467411545624, 'fraction_numerical': 0.0074487895716946, 'mean_word_length': 5.595092024539877, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
From RNA‐seq to Immunohistochemistry: Keratin 17 Defines Pancreatic Cancer Subtypes

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal disease, in part because of the lack of molecular biomarkers, allowing the rationale assignment of patient subgroups to appropriate targeted therapies. As a result, almost all PDAC patients are treated with one of two chemotherapeutic regimens (Gem/Abraxane or FOLFIRINOX), with marginal improvement in overall survival. In the last two years, RNA sequencing (RNASeq) studies reported that mRNA expression from bulk tumor defines molecular subtypes of PDAC that are highly correlated with survival. The 25‐gene mRNA signature defining the clinically most aggressive subtype of PDAC has yielded a refined landscape through which biomarker and targetable therapeutics can be identified. Thus, the aim of the current study was to determine if K17, one member of this mRNA signature, is sufficient to define the most aggressive subtype of PDAC and to validate K17 by immunohistochemistry (IHC) as a negative prognostic biomarker.